<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02397447</url>
  </required_header>
  <id_info>
    <org_study_id>MCHDM2</org_study_id>
    <nct_id>NCT02397447</nct_id>
  </id_info>
  <brief_title>Effect of Momordica Charantia Administration on Type 2 Diabetes Mellitus, Insulin Sensitivity and Insulin Secretion</brief_title>
  <official_title>Effect of Momordica Charantia Administration on Insulin Sensitivity and Insulin Secretion in Patients With Type 2 Diabetes Mellitus, Without Pharmacological Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Guadalajara</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Guadalajara</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypoglycemic effect of Momordica Charantia has been evaluated in clinical trials in&#xD;
      patients with type 2 diabetes mellitus. Important reductions in fasting plasma glucose,&#xD;
      glycated hemoglobin (A1C), and fructosamine were observed. It is unknown whether this&#xD;
      improvement is due to an improvement in insulin sensitivity and insulin secretion. The&#xD;
      purpose of this study is to evaluate the effect of the administration of Momordica Charantia&#xD;
      on insulin sensitivity and insulin secretion in patients with type 2 diabetes mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A randomized, double-blind, placebo controlled clinical trial is carried out in 24 patients&#xD;
      with diagnosis of diabetes mellitus type 2 according to the criteria of the American Diabetes&#xD;
      Association. Patients are assigned to two different arms: one group receives Momordica&#xD;
      Charantia, 2 capsules with 500 mg twice daily before breakfast and dinner for 90 days or&#xD;
      placebo, under the same scheme of treatment.&#xD;
&#xD;
      An oral glucose tolerance test is performed before and after the intervention. Matsuda index,&#xD;
      Stumvoll index and Insulinogenic index are calculated to assess insulin sensitivity and&#xD;
      insulin secretion.&#xD;
&#xD;
      Other clinical and laboratory parameters that are evaluated include: Body weight, body mass&#xD;
      index, waist circumference, blood pressure, body fat percentage, fasting plasma glucose, A1C,&#xD;
      creatinine, lipid profile and liver transaminases.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total and First Phase of Insulin Secretion (Insulinogenic Index and Stumvoll Index) After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>Total insulin secretion and first phase of insulin secretion were estimated at baseline and after 90 days using the insulinogenic index (ΔABC insulin / ΔABC glucose) and the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), respectively</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Insulin Sensitivity (Matsuda Index) After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>Insulin sensitivity was calculated at baseline and after 90 days with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasting Serum Glucose (FSG) After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The glucose oxidase technique (Beckman Instruments, Inc., Brea, CA, USA) was used to determine fasting serum glucose at baseline and after 90 days with an intra- and interassay coefficient of variation of&lt;1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>A1C After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>A liquid chromatography method was used to evaluate A1C at baseline and after 90 days (Bio-Rad Laboratories, Hercules, CA, USA) with an intra and inter assay coefficient of variation of 0.4% and 1.6%, respectively</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Cholesterol After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The blood sample for the determination of total cholesterol was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Triglycerides After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The blood sample for the determination of triglycerides was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High Density Lipoprotein Cholesterol (HDL-c) After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The blood sample for the determination of high density lipoprotein cholesterol was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Low Density Lipoprotein Cholesterol (LDL-c) After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The blood sample for the determination of low density lipoprotein cholesterol was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Very Low Density Lipoprotein After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The blood sample for the determination of VLDL was taken after an overnight fast and was calculated at baseline and after 90 days as triglycerides/5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alanine Aminotransferase (ALT) After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The blood sample for the determination of ALT was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aspartate Aminotransferase (AST) After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The blood sample for the determination of AST was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Creatinine After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The blood sample for the determination of creatinine was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systolic Blood Pressure After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The systolic blood pressure was evaluated at baseline and after 90 days with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of SBP. The value was expressed on mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic Blood Pressure After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The diastolic blood pressure was evaluated at baseline and after 90 days with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of DBP. The value was expressed on mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight (BW) After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The body weight was evaluated at baseline and after 90 days after an overnight fast, through a bioimpedance digital scale results are reported in kilograms with a decimal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI) After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The BMI was calculated at baseline and after 90 days by the square of the body height, and is universally expressed in units of kg/m^2, resulting from mass in kilograms and height in metres</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fat Mass After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>Fat mass was measured at baseline and after 90 days with an electric bioimpedance scale (Model TBF-300 A; Tanita Corporation of America Inc., Arlington Heights, IL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist Circumference (WC) After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The waist circumference was evaluated at baseline and after 90 days after an overnight fast with a flexible tape in the midpoint between the lowest rib and the iliac crest and is expressed in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-h Serum Glucose After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The glucose oxidase technique (Beckman Instruments, Inc., Brea, CA, USA) was used to determine serum glucose at baseline and after 90 days with an intra- and interassay coefficient of variation of&lt;1%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC-glucose After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The polygonal formula was used to calculate area under the curve (AUC) of glucose at baseline and after 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC-insulin After 90 Days</measure>
    <time_frame>90 days</time_frame>
    <description>The polygonal formula was used to calculate area under the curve (AUC) of insulin at baseline and after 90 days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus Type 2</condition>
  <arm_group>
    <arm_group_label>Momordica charantia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Momordica charantia</intervention_name>
    <description>Momordica Charantia: 2000 mg per day for three months</description>
    <arm_group_label>Momordica charantia</arm_group_label>
    <other_name>Bitter gourd, karela, balsam-pear</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo: 2000 mg per day for three months</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Calcined magnesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of diabetes mellitus type 2 according to the criteria of the American&#xD;
             Diabetes Association (&lt;5 years), without pharmacological treatment (oral antidiabetic&#xD;
             drugs or insulin) at least for three months before entering the study&#xD;
&#xD;
          -  Fasting glucose: &lt;210 mg/dl&#xD;
&#xD;
          -  A1C: 7-9%&#xD;
&#xD;
          -  Body mass index: 25-34.9 kg/m2&#xD;
&#xD;
          -  Body weight without variations above or under 5% in the last three months before&#xD;
             entering the study&#xD;
&#xD;
          -  Women in childbearing years must have a contraceptive method&#xD;
&#xD;
          -  Letter of consent and release signed by each patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or suspected pregnant women&#xD;
&#xD;
          -  Woman breastfeeding&#xD;
&#xD;
          -  Medications known to affect metabolism of glucose and insulin&#xD;
&#xD;
          -  Personal history of liver or renal disease&#xD;
&#xD;
          -  Hypertension, thyroid or cardiovascular disease decompensated&#xD;
&#xD;
          -  Total cholesterol &gt;= 240mg/dl, triglycerides &gt;=400mg/dl, glomerular filtration rate&#xD;
             &lt;=60ml/min or liver transaminases &gt;=2.5 the upper normal limit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esperanza Martínez Abundis, PhD Science</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Experimental and Clinical Therapeutics (INTEC), CUCS, University of Guadalajara</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2015</study_first_posted>
  <results_first_submitted>September 6, 2020</results_first_submitted>
  <results_first_submitted_qc>September 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2020</results_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Guadalajara</investigator_affiliation>
    <investigator_full_name>Esperanza Martínez-Abundis</investigator_full_name>
    <investigator_title>PhD. Esperanza Martínez-Abundis</investigator_title>
  </responsible_party>
  <keyword>Momordica Charantia</keyword>
  <keyword>Insulin secretion</keyword>
  <keyword>Insulin sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Momordica Charantia</title>
          <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Momordica Charantia</title>
          <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.1" spread="7.3"/>
                    <measurement group_id="B2" value="47" spread="7.4"/>
                    <measurement group_id="B3" value="48.6" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight (BW)</title>
          <description>The BW was evaluated after an overnight fast, through a bioimpedance digital scale results are reported in kilograms with a decimal.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.4" spread="9.2"/>
                    <measurement group_id="B2" value="73.6" spread="11.1"/>
                    <measurement group_id="B3" value="76.5" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index (BMI)</title>
          <description>The BMI was calculated by the square of the body height, and is universally expressed in units of kg/m2, resulting from mass in kilograms and height in metres.</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="2.4"/>
                    <measurement group_id="B2" value="28.8" spread="3.9"/>
                    <measurement group_id="B3" value="28.9" spread="3.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fat mass</title>
          <description>Fat mass was measured with an electric bioimpedance scale (Model TBF-300 A; Tanita Corporation of America Inc., Arlington Heights, IL)</description>
          <units>body fat percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.7" spread="7.8"/>
                    <measurement group_id="B2" value="35.2" spread="8.1"/>
                    <measurement group_id="B3" value="36.0" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist circumference (WC)</title>
          <description>The WC was evaluated after an overnight fast with a flexible tape in the midpoint between the lowest rib and the iliac crest and is expressed in centimeters</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106" spread="12"/>
                    <measurement group_id="B2" value="97" spread="11"/>
                    <measurement group_id="B3" value="101.9" spread="12.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure (SBP)</title>
          <description>The SBP was evaluated with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of SBP. The value was expressed on mmHg.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="119.5" spread="8.9"/>
                    <measurement group_id="B2" value="116.5" spread="10.8"/>
                    <measurement group_id="B3" value="118.0" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure (DBP)</title>
          <description>The DBP was evaluated with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of DBP. The value was expressed on mmHg</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75" spread="4.7"/>
                    <measurement group_id="B2" value="74.2" spread="5.5"/>
                    <measurement group_id="B3" value="74.6" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>A1C</title>
          <description>A liquid chromatography method was used (Bio-Rad Laboratories, Hercules, CA, USA) with an intra and inter assay coefficient of variation of 0.4% and 1.6%, respectively</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.8" spread="0.8"/>
                    <measurement group_id="B2" value="7.6" spread="0.6"/>
                    <measurement group_id="B3" value="7.7" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fasting serum glucose (FSG)</title>
          <description>The glucose oxidase technique (Beckman Instruments, Inc., Brea, CA, USA) was used to determine serum glucose with an intra- and interassay coefficient of variation of&lt;1%</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="1.4"/>
                    <measurement group_id="B2" value="7.1" spread="1.9"/>
                    <measurement group_id="B3" value="7.6" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2-h serum glucose</title>
          <description>The glucose oxidase technique (Beckman Instruments, Inc., Brea, CA, USA) was used to determine serum glucose with an intra- and interassay coefficient of variation of&lt;1%</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.1" spread="3.7"/>
                    <measurement group_id="B2" value="14.9" spread="4.7"/>
                    <measurement group_id="B3" value="16.0" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AUC-glucose</title>
          <description>The polygonal formula was used to calculate area under the curve (AUC) of glucose and insulin</description>
          <units>mmol/L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1840" spread="295"/>
                    <measurement group_id="B2" value="1670" spread="380"/>
                    <measurement group_id="B3" value="1754.1" spread="344.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>AUC-insulin</title>
          <description>The polygonal formula was used to calculate area under the curve (AUC) of glucose and insulin</description>
          <units>pmol/L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56562" spread="36078"/>
                    <measurement group_id="B2" value="41334" spread="22356"/>
                    <measurement group_id="B3" value="48951" spread="30369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Insulinogenic index (total insulin secretion)</title>
          <description>Total insulin secretion was calculated with the insulinogenic index (ΔABC insulin / ΔABC glucose)</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.29" spread="0.18"/>
                    <measurement group_id="B2" value="0.23" spread="0.14"/>
                    <measurement group_id="B3" value="0.26" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stumvoll index (first phase of insulin secretion)</title>
          <description>First phase of insulin secretion was estimated using the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0')</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="557.8" spread="645.6"/>
                    <measurement group_id="B2" value="419.3" spread="769.1"/>
                    <measurement group_id="B3" value="488.6" spread="698.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Matsuda index (insulin sensitivity)</title>
          <description>Insulin sensitivity was calculated with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.4" spread="1.4"/>
                    <measurement group_id="B2" value="3.8" spread="4.6"/>
                    <measurement group_id="B3" value="3.1" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol</title>
          <description>The blood sample for the determination of total cholesterol was taken after an overnight fast and was evaluated by spectrophotometry method</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.89" spread="0.73"/>
                    <measurement group_id="B2" value="4.41" spread="0.75"/>
                    <measurement group_id="B3" value="4.65" spread="0.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Triglycerides</title>
          <description>The blood sample for the determination of triglycerides was taken after an overnight fast and was evaluated by spectrophotometry method</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.31" spread="1.25"/>
                    <measurement group_id="B2" value="2.19" spread="0.76"/>
                    <measurement group_id="B3" value="2.25" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-density lipoprotein cholesterol (HDL-c)</title>
          <description>The blood sample for the determination of HDL-c was taken after an overnight fast and was evaluated by spectrophotometry method</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.13" spread="0.18"/>
                    <measurement group_id="B2" value="1.04" spread="0.23"/>
                    <measurement group_id="B3" value="1.09" spread="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Low-density lipoprotein cholesterol (LDL-c)</title>
          <description>The blood sample for the determination of LDL-C was taken after an overnight fast and was calculated by Friedewald formula</description>
          <units>mmol/L</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.69" spread="0.80"/>
                    <measurement group_id="B2" value="2.35" spread="0.64"/>
                    <measurement group_id="B3" value="2.52" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Very low-density lipoprotein (VLDL)</title>
          <description>The blood sample for the determination of VLDL was taken after an overnight fast and was calculated as triglycerides/5</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.26" spread="4.48"/>
                    <measurement group_id="B2" value="7.86" spread="2.7"/>
                    <measurement group_id="B3" value="8.07" spread="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Creatinine</title>
          <description>The blood sample for the determination of creatinine was taken after an overnight fast and was evaluated by spectrophotometry method</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70.72" spread="8.84"/>
                    <measurement group_id="B2" value="61.88" spread="8.84"/>
                    <measurement group_id="B3" value="70.36" spread="8.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Alanine aminotransferase (ALT)</title>
          <description>The blood sample for the determination of ALT was taken after an overnight fast and was evaluated by spectrophotometry method</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35.4" spread="24.4"/>
                    <measurement group_id="B2" value="36.0" spread="19.7"/>
                    <measurement group_id="B3" value="35.71" spread="21.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Aspartate aminotransferase (AST)</title>
          <description>The blood sample for the determination of AST was taken after an overnight fast and was evaluated by spectrophotometry method</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.0" spread="22.4"/>
                    <measurement group_id="B2" value="23.1" spread="11.3"/>
                    <measurement group_id="B3" value="26.08" spread="17.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Total and First Phase of Insulin Secretion (Insulinogenic Index and Stumvoll Index) After 90 Days</title>
        <description>Total insulin secretion and first phase of insulin secretion were estimated at baseline and after 90 days using the insulinogenic index (ΔABC insulin / ΔABC glucose) and the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), respectively</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Total and First Phase of Insulin Secretion (Insulinogenic Index and Stumvoll Index) After 90 Days</title>
          <description>Total insulin secretion and first phase of insulin secretion were estimated at baseline and after 90 days using the insulinogenic index (ΔABC insulin / ΔABC glucose) and the Stumvoll index (1283+ 1.829 x insulin 30' - 138.7 x glucose 30' + 3.772 x insulin 0'), respectively</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total insulin secretion (Insulinogenic index)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.29"/>
                    <measurement group_id="O2" value="0.23" spread="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Phase of Insulin Secretion (Stumvoll index)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1135.7" spread="725.0"/>
                    <measurement group_id="O2" value="309.0" spread="776.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Insulin Sensitivity (Matsuda Index) After 90 Days</title>
        <description>Insulin sensitivity was calculated at baseline and after 90 days with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Sensitivity (Matsuda Index) After 90 Days</title>
          <description>Insulin sensitivity was calculated at baseline and after 90 days with Matsuda index [10,000 / √glucose 0' x insulin 0') (mean glucose oral glucose tolerance test (OGTT) x mean insulin OGTT)]</description>
          <units>index</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" spread="1.6"/>
                    <measurement group_id="O2" value="2.3" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Serum Glucose (FSG) After 90 Days</title>
        <description>The glucose oxidase technique (Beckman Instruments, Inc., Brea, CA, USA) was used to determine fasting serum glucose at baseline and after 90 days with an intra- and interassay coefficient of variation of&lt;1</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Serum Glucose (FSG) After 90 Days</title>
          <description>The glucose oxidase technique (Beckman Instruments, Inc., Brea, CA, USA) was used to determine fasting serum glucose at baseline and after 90 days with an intra- and interassay coefficient of variation of&lt;1</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" spread="2.9"/>
                    <measurement group_id="O2" value="7.2" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>A1C After 90 Days</title>
        <description>A liquid chromatography method was used to evaluate A1C at baseline and after 90 days (Bio-Rad Laboratories, Hercules, CA, USA) with an intra and inter assay coefficient of variation of 0.4% and 1.6%, respectively</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>A1C After 90 Days</title>
          <description>A liquid chromatography method was used to evaluate A1C at baseline and after 90 days (Bio-Rad Laboratories, Hercules, CA, USA) with an intra and inter assay coefficient of variation of 0.4% and 1.6%, respectively</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="1.3"/>
                    <measurement group_id="O2" value="7.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Cholesterol After 90 Days</title>
        <description>The blood sample for the determination of total cholesterol was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Total Cholesterol After 90 Days</title>
          <description>The blood sample for the determination of total cholesterol was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.68" spread="1.02"/>
                    <measurement group_id="O2" value="4.39" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Triglycerides After 90 Days</title>
        <description>The blood sample for the determination of triglycerides was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Triglycerides After 90 Days</title>
          <description>The blood sample for the determination of triglycerides was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.93" spread="0.92"/>
                    <measurement group_id="O2" value="2.02" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Density Lipoprotein Cholesterol (HDL-c) After 90 Days</title>
        <description>The blood sample for the determination of high density lipoprotein cholesterol was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>High Density Lipoprotein Cholesterol (HDL-c) After 90 Days</title>
          <description>The blood sample for the determination of high density lipoprotein cholesterol was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" spread="0.31"/>
                    <measurement group_id="O2" value="1.09" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Low Density Lipoprotein Cholesterol (LDL-c) After 90 Days</title>
        <description>The blood sample for the determination of low density lipoprotein cholesterol was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Low Density Lipoprotein Cholesterol (LDL-c) After 90 Days</title>
          <description>The blood sample for the determination of low density lipoprotein cholesterol was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.75" spread="0.96"/>
                    <measurement group_id="O2" value="2.41" spread="0.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Very Low Density Lipoprotein After 90 Days</title>
        <description>The blood sample for the determination of VLDL was taken after an overnight fast and was calculated at baseline and after 90 days as triglycerides/5</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Very Low Density Lipoprotein After 90 Days</title>
          <description>The blood sample for the determination of VLDL was taken after an overnight fast and was calculated at baseline and after 90 days as triglycerides/5</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.92" spread="3.32"/>
                    <measurement group_id="O2" value="7.22" spread="1.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Alanine Aminotransferase (ALT) After 90 Days</title>
        <description>The blood sample for the determination of ALT was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Alanine Aminotransferase (ALT) After 90 Days</title>
          <description>The blood sample for the determination of ALT was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.1" spread="19.4"/>
                    <measurement group_id="O2" value="38.2" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aspartate Aminotransferase (AST) After 90 Days</title>
        <description>The blood sample for the determination of AST was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Aspartate Aminotransferase (AST) After 90 Days</title>
          <description>The blood sample for the determination of AST was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
          <units>U/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.9" spread="16.5"/>
                    <measurement group_id="O2" value="24.4" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Creatinine After 90 Days</title>
        <description>The blood sample for the determination of creatinine was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Creatinine After 90 Days</title>
          <description>The blood sample for the determination of creatinine was taken after an overnight fast and was evaluated at baseline and after 90 days by spectrophotometry method</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.72" spread="35.36"/>
                    <measurement group_id="O2" value="79.56" spread="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Systolic Blood Pressure After 90 Days</title>
        <description>The systolic blood pressure was evaluated at baseline and after 90 days with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of SBP. The value was expressed on mmHg</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Systolic Blood Pressure After 90 Days</title>
          <description>The systolic blood pressure was evaluated at baseline and after 90 days with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of SBP. The value was expressed on mmHg</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="119.6" spread="9.5"/>
                    <measurement group_id="O2" value="115.4" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Diastolic Blood Pressure After 90 Days</title>
        <description>The diastolic blood pressure was evaluated at baseline and after 90 days with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of DBP. The value was expressed on mmHg</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Diastolic Blood Pressure After 90 Days</title>
          <description>The diastolic blood pressure was evaluated at baseline and after 90 days with a digital sphygmomanometer with the subject sited down on a chair after a resting period of 5 minutes on three occasions. The mean of the three measures was considered as the value of DBP. The value was expressed on mmHg</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.1" spread="6.5"/>
                    <measurement group_id="O2" value="72.6" spread="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight (BW) After 90 Days</title>
        <description>The body weight was evaluated at baseline and after 90 days after an overnight fast, through a bioimpedance digital scale results are reported in kilograms with a decimal.</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight (BW) After 90 Days</title>
          <description>The body weight was evaluated at baseline and after 90 days after an overnight fast, through a bioimpedance digital scale results are reported in kilograms with a decimal.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.0" spread="9.2"/>
                    <measurement group_id="O2" value="73.4" spread="10.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Mass Index (BMI) After 90 Days</title>
        <description>The BMI was calculated at baseline and after 90 days by the square of the body height, and is universally expressed in units of kg/m^2, resulting from mass in kilograms and height in metres</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Body Mass Index (BMI) After 90 Days</title>
          <description>The BMI was calculated at baseline and after 90 days by the square of the body height, and is universally expressed in units of kg/m^2, resulting from mass in kilograms and height in metres</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" spread="1.9"/>
                    <measurement group_id="O2" value="28.9" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fat Mass After 90 Days</title>
        <description>Fat mass was measured at baseline and after 90 days with an electric bioimpedance scale (Model TBF-300 A; Tanita Corporation of America Inc., Arlington Heights, IL)</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Fat Mass After 90 Days</title>
          <description>Fat mass was measured at baseline and after 90 days with an electric bioimpedance scale (Model TBF-300 A; Tanita Corporation of America Inc., Arlington Heights, IL)</description>
          <units>percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.3" spread="7.6"/>
                    <measurement group_id="O2" value="35.8" spread="6.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Waist Circumference (WC) After 90 Days</title>
        <description>The waist circumference was evaluated at baseline and after 90 days after an overnight fast with a flexible tape in the midpoint between the lowest rib and the iliac crest and is expressed in centimeters</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>Waist Circumference (WC) After 90 Days</title>
          <description>The waist circumference was evaluated at baseline and after 90 days after an overnight fast with a flexible tape in the midpoint between the lowest rib and the iliac crest and is expressed in centimeters</description>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" spread="11"/>
                    <measurement group_id="O2" value="98" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-h Serum Glucose After 90 Days</title>
        <description>The glucose oxidase technique (Beckman Instruments, Inc., Brea, CA, USA) was used to determine serum glucose at baseline and after 90 days with an intra- and interassay coefficient of variation of&lt;1%</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>2-h Serum Glucose After 90 Days</title>
          <description>The glucose oxidase technique (Beckman Instruments, Inc., Brea, CA, USA) was used to determine serum glucose at baseline and after 90 days with an intra- and interassay coefficient of variation of&lt;1%</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="4.3"/>
                    <measurement group_id="O2" value="14.3" spread="4.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC-glucose After 90 Days</title>
        <description>The polygonal formula was used to calculate area under the curve (AUC) of glucose at baseline and after 90 days</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>AUC-glucose After 90 Days</title>
          <description>The polygonal formula was used to calculate area under the curve (AUC) of glucose at baseline and after 90 days</description>
          <units>mmol/L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1576" spread="391"/>
                    <measurement group_id="O2" value="1663" spread="363"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC-insulin After 90 Days</title>
        <description>The polygonal formula was used to calculate area under the curve (AUC) of insulin at baseline and after 90 days</description>
        <time_frame>90 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Momordica Charantia</title>
            <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
          </group>
        </group_list>
        <measure>
          <title>AUC-insulin After 90 Days</title>
          <description>The polygonal formula was used to calculate area under the curve (AUC) of insulin at baseline and after 90 days</description>
          <units>pmol/L/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65256" spread="42720"/>
                    <measurement group_id="O2" value="41310" spread="20292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected throughout the 90 days of the study</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Momordica Charantia</title>
          <description>Two 500 mg capsules of Momordica Charantia twice daily before breakfast and dinner for 90 days&#xD;
Momordica charantia: Momordica Charantia: 2000 mg per day for three months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Two 500 mg capsules of calcined magnesia twice daily before breakfast and dinner for 90 days&#xD;
Placebo: Placebo: 2000 mg per day for three months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dra. Esperanza Martínez Abundis</name_or_title>
      <organization>Institute of Experimental and Clinical Therapeutics</organization>
      <phone>+52-33-10-58-52-00 ext 34211</phone>
      <email>esperanzamartnezabundi@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

